{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:01:50Z","timestamp":1785132110622,"version":"3.55.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare inflammatory demyelinating disorder of the central nervous system. During the acute phase, management typically prioritizes high-dose methylprednisolone pulse therapy. When the patients show inadequate response, intravenous immunoglobulin (IVIG) or plasma exchange is recommended. We report the case of a 17-year-old male of Mongolian ethnicity who developed severe visual impairment following treatment for Epstein-Barr virus (EBV) meningitis, ultimately diagnosed with MOGAD. Following both methylprednisolone pulse therapy and IVIG, the patient exhibited a suboptimal response. However, his symptoms improved markedly after treatment with eculizumab. Subsequently, sequential therapy with ofatumumab was applied. At the six-month follow-up, the patient remained relapse-free and reported no adverse effects. This case suggests that eculizumab can serve as an effective salvage therapy for acute MOGAD refractory to conventional treatment. Ofatumumab may be a viable option for maintenance therapy during remission. These findings may provide valuable insights for future clinical research.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1861880","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:41:08Z","timestamp":1785130868000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Eculizumab treatment in the salvage therapy of MOGAD: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuzhou","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Inner Mongolia Medical University","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Inner Mongolia Medical University","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhelin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Inner Mongolia Medical University","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s00415-024-12861-9","article-title":"MOG antibody-associated disease epidemiology in Olmsted County, USA, and Martinique","volume":"272","author":"Cacciaguerra","year":"2025","journal-title":"J Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26226","article-title":"Complement activation is a prominent feature of MOGAD","volume":"90","author":"Keller","year":"2021","journal-title":"Ann Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26890","article-title":"Epstein-Barr virus strongly associates with pediatric multiple sclerosis, but not myelin oligodendrocyte glycoprotein-antibody-associated disease","volume":"95","author":"Fadda","year":"2024","journal-title":"Ann Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1013413","article-title":"Case report: MOG-IgG-associated encephalitis with Epstein-Barr virus infection and Alzheimer's pathologic change in cerebrospinal fluid","volume":"13","author":"Li","year":"2022","journal-title":"Front Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12883-017-0858-6","article-title":"Anti-MOG antibody-positive ADEM following infectious mononucleosis due to a primary EBV infection: a case report","volume":"17","author":"Nakamura","year":"2017","journal-title":"BMC Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1510097","article-title":"Ofatumumab successfully treats myelin oligodendrocyte glycoprotein antibody-associated disease accompanied by Epstein-Barr viral infection: a case series","volume":"15","author":"Min","year":"2024","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417151","article-title":"Epstein-Barr virus and human endogenous retrovirus in Japanese patients with autoimmune demyelinating disorders","volume":"24","author":"Cossu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"New Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1530977","article-title":"Translational insights from EAE models: decoding MOGAD pathogenesis and therapeutic innovation","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2300648120","article-title":"Dissection of complement and Fc-receptor-mediated pathomechanisms of autoantibodies to myelin oligodendrocyte glycoprotein","volume":"120","author":"Mader","year":"2023","journal-title":"P Natl Acad Sci USA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.165373","article-title":"MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity","volume":"8","author":"Yandamuri","year":"2023","journal-title":"JCI Insight"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1014071","article-title":"Complement-dependent cytotoxicity of human autoantibodies against myelin oligodendrocyte glycoprotein","volume":"17","author":"Kohyama","year":"2023","journal-title":"Front Neurosci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-334764","article-title":"Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD","volume":"96","author":"H\u00e4u\u00dfler","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25648","article-title":"Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1861880\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:41:09Z","timestamp":1785130869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1861880\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":19,"alternative-id":["10.3389\/fimmu.2026.1861880"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1861880","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1861880"}}